Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

Completed · Phase 2

Conditions studied: Venous Thromboembolism, Deep Venous Thrombosis, Surgery

In brief

The aim of this research is to better understand how patient-level factors can be used to predict the appropriate enoxaparin dose to maximize venous thromboembolism (VTE) risk reduction and minimize bleeding.

Key facts

Study ID

NCT03251963

Run by

University of Utah

People needed

131

Starts

2017-09-15

Expected to finish

2019-07-27

Last updated by the study team

2020-07-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• receiving Video-Assisted Thoracoscopic Surgery
• able to have Enoxaparin initiated within 8 hours after procedure

You may not qualify if…

• Contraindication to use of enoxaparin
• Intracranial bleeding/stroke
• Hematoma or bleeding disorder
• Heparin-induced thrombocytopenia positive
• Creatinine clearance less than or equal to 30 mL/min
• Serum creatinine greater than 1.6 mg/dL
• Epidural catheter

Where it is running

• University of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.